80 related articles for article (PubMed ID: 38592437)
1. TNA-Mediated Antisense Strategy to Knockdown Akt Genes for Triple-Negative Breast Cancer Therapy.
Li P; Zheng S; Leung HM; Liu LS; Chang TJH; Maryam A; Wang F; Chin YR; Lo PK
Small Methods; 2024 May; ():e2400291. PubMed ID: 38779741
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of novel phthalazine-based derivatives with potent cytotoxicity against HCT-116 cells through apoptosis and VEGFR2 inhibition.
El Sayed D; El Rayes SM; Soliman HA; AlBalaa IE; Alturki MS; Al Khzem AH; Alsharif MA; Nafie MS
RSC Adv; 2024 Apr; 14(19):13027-13043. PubMed ID: 38660526
[TBL] [Abstract][Full Text] [Related]
3. Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements.
Hattab D; Bakhtiar A
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33003468
[TBL] [Abstract][Full Text] [Related]
4. Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies.
Abdulmalek SA; Saleh AM; Shahin YR; El Azab EF
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; ():. PubMed ID: 38592437
[TBL] [Abstract][Full Text] [Related]
5. Bee venom-loaded EGFR-targeting peptide-coupled chitosan nanoparticles for effective therapy of hepatocellular carcinoma by inhibiting EGFR-mediated MEK/ERK pathway.
Abdulmalek S; Mostafa N; Gomaa M; El-Kersh M; Elkady AI; Balbaa M
PLoS One; 2022; 17(8):e0272776. PubMed ID: 35947632
[TBL] [Abstract][Full Text] [Related]
6. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
7. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.
Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW
Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267
[TBL] [Abstract][Full Text] [Related]
8. Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles.
Fahmy SA; Mahdy NK; Mohamed AH; Mokhtar FA; Youness RA
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396746
[TBL] [Abstract][Full Text] [Related]
9. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
10. Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine.
Yang F; Fan Z; Zhang L; He Y; Hu R; Xiang J; Fu S; Wang G; Wang J; Tao X; Zhang P
Discov Nano; 2023 Sep; 18(1):119. PubMed ID: 37735318
[TBL] [Abstract][Full Text] [Related]
11. Curcumin and melphalan cotreatment induces cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells.
Passos CLA; Polinati RM; Ferreira C; Dos Santos NAN; Lima DGV; da Silva JL; Fialho E
Sci Rep; 2023 Aug; 13(1):13446. PubMed ID: 37596331
[TBL] [Abstract][Full Text] [Related]
12. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.
Scully MA; Wilkins DE; Dang MN; Hoover EC; Aboeleneen SB; Day ES
Mol Pharm; 2023 Aug; 20(8):3895-3913. PubMed ID: 37459272
[TBL] [Abstract][Full Text] [Related]
13. Potential lifetime effects caused by cellular uptake of nanoplastics: A review.
Lee Y; Cho S; Park K; Kim T; Kim J; Ryu DY; Hong J
Environ Pollut; 2023 Jul; 329():121668. PubMed ID: 37087090
[TBL] [Abstract][Full Text] [Related]
14. SRPKs: a promising therapeutic target in cancer.
Tufail M; Wu C
Clin Exp Med; 2023 Nov; 23(7):3093-3112. PubMed ID: 37027068
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
